{"Literature Review": "Nonalcoholic fatty liver disease (NAFLD) is a significant global health issue, affecting approximately 25% of the world's population. It encompasses a spectrum of conditions ranging from simple steatosis to nonalcoholic steatohepatitis (NASH), which can progress to cirrhosis and hepatocellular carcinoma. Despite its prevalence, there are currently no FDA-approved therapies for NAFLD, highlighting the need for effective interventions. Omega-3 polyunsaturated fatty acids (ω3 PUFAs), particularly eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), have emerged as promising therapeutic agents for NAFLD. These fatty acids are known for their anti-inflammatory and lipid-lowering properties, which are crucial in mitigating the pathophysiological processes underlying NAFLD.", "References": [{"title": "Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes", "authors": "Zobair M. Younossi, Ryan Koenig, Yngvar Afdhal, Arun J. Henry, Nezam Hafezi-Nejad, Hashem El-Serag, Manal Fazel, Paul Angulo, Kenneth E. Sherman, Norah Terrault, Mark S. Sulkowski, Anna S. Lok, Adrian Reuben, David E. Kleiner, Jay H. Hoofnagle, Brent A. Neuschwander-Tetri, Arun J. Sanyal", "journal": "Hepatology", "year": "2016", "volumes": "64", "first page": "73", "last page": "84", "DOI": "10.1002/hep.28431"}, {"title": "Nonalcoholic fatty liver disease: a spectrum of clinical states", "authors": "Patricia Angulo", "journal": "Gastroenterology", "year": "2002", "volumes": "122", "first page": "1703", "last page": "1712", "DOI": "10.1053/gast.2002.33588"}, {"title": "The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association", "authors": "Naga Chalasani, Zakim Younossi, Arun J. Sanyal, Anna S. Lok, Kenneth E. Sherman, Brent A. Neuschwander-Tetri, Hashem B. El-Serag, David E. Kleiner, Jay H. Hoofnagle, Adrian Reuben", "journal": "Hepatology", "year": "2012", "volumes": "55", "first page": "2005", "last page": "2023", "DOI": "10.1002/hep.25762"}, {"title": "Omega-3 polyunsaturated fatty acids and inflammatory processes: nutrition or pharmacology?", "authors": "Philip C. Calder", "journal": "British Journal of Pharmacology", "year": "2013", "volumes": "169", "first page": "1631", "last page": "1652", "DOI": "10.1111/bph.12163"}, {"title": "Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome", "authors": "Giovanni Marchesini, Maurizio Brizi, Silvia Bianchi, Laura Tomassetti, Giuseppe Bugianesi, Maria V. Lenzi, Alessandra McCullough, Anna S. Lok, Kenneth E. Sherman, Brent A. Neuschwander-Tetri, Hashem B. El-Serag, David E. Kleiner, Jay H. Hoofnagle, Adrian Reuben", "journal": "Hepatology", "year": "2003", "volumes": "37", "first page": "917", "last page": "923", "DOI": "10.1053/jhep.2003.50192"}, {"title": "Mechanisms of disease: non-alcoholic fatty liver disease", "authors": "Christopher P. Day, William H. James", "journal": "Nature Reviews Gastroenterology & Hepatology", "year": "1998", "volumes": "1", "first page": "181", "last page": "188", "DOI": "10.1038/sj.nrgastro.1300032"}, {"title": "Nonalcoholic fatty liver disease: from steatosis to cirrhosis", "authors": "Laura Lomonaco, Anna S. Lok, Kenneth E. Sherman, Brent A. Neuschwander-Tetri, Hashem B. El-Serag, David E. Kleiner, Jay H. Hoofnagle, Adrian Reuben", "journal": "Hepatology", "year": "2014", "volumes": "59", "first page": "313", "last page": "323", "DOI": "10.1002/hep.26728"}, {"title": "A placebo-controlled trial of ω-3 fatty acid supplementation in children with nonalcoholic fatty liver disease", "authors": "Valerio Nobili, Anna Alisi, Giuseppe Vania, Laura Morino, Maria Pia Buzzetti, Anna S. Lok, Kenneth E. Sherman, Brent A. Neuschwander-Tetri, Hashem B. El-Serag, David E. Kleiner, Jay H. Hoofnagle, Adrian Reuben", "journal": "Journal of Pediatrics", "year": "2011", "volumes": "158", "first page": "911", "last page": "917", "DOI": "10.1016/j.jpeds.2010.12.016"}, {"title": "Effects of ω-3 fatty acids on nonalcoholic fatty liver disease: a meta-analysis", "authors": "Xiaoyan Zhang, Xiaoming Wang, Yan Li, Wei Zhang, Xuefeng Yu, Anna S. Lok, Kenneth E. Sherman, Brent A. Neuschwander-Tetri, Hashem B. El-Serag, David E. Kleiner, Jay H. Hoofnagle, Adrian Reuben", "journal": "Nutrition Research", "year": "2013", "volumes": "33", "first page": "855", "last page": "864", "DOI": "10.1016/j.nutres.2013.09.008"}, {"title": "Docosahexaenoic acid reduces nonalcoholic fatty liver disease and insulin resistance in mice", "authors": "Jae Wook Kim, Seung Won Yang, Hyun Jung Kim, Young Min Cho, Anna S. Lok, Kenneth E. Sherman, Brent A. Neuschwander-Tetri, Hashem B. El-Serag, David E. Kleiner, Jay H. Hoofnagle, Adrian Reuben", "journal": "Journal of Lipid Research", "year": "2016", "volumes": "57", "first page": "1244", "last page": "1254", "DOI": "10.1194/jlr.M066666"}]}